Paul Crispen MD

“Other treatments in the bladder are typically administered once a week for six weeks,” Crispen said. “Offering longer intervals between treatments is favorable for these patients, leading to fewer office visits, co-pays, catheterizations and everything else that goes along with the process.” If successful, Crispen said new treatment agents may even replace intravesical BCG as the primary therapy for high-risk NMIBC. BCG treatments are highly toxic, with potentially serious complications; in fact, fewer than 20% of patients are able to tolerate all doses of BCG maintenance therapy.

Core Lecture: "Testis Cancer Part 2" Tuesday, 10/25/22 7:00 am

Core Lecture: "Testis Cancer" Tuesday, 8/23/22 7:00 am

“We are extremely fortunate to have experts in all areas of kidney cancer treatment at UF Health,” said Li-Ming Su, MD, chair of the department of urology.

Core Lecture with Dr. Paul Crispen: "CIS of the Bladder" | Tuesday, 9/28/21 at 7:00 am

The official podcast of UF Health provides engaging insight on today’s trending health care topics. Earn CME credits while learning about clinical issues and research advances from experts at UF Health Shands Hospital, one of the nation’s top academic health centers. Subscribe to UF Health MedEd Cast and join the conversation!

Bladder cancer is the second most common urologic cancer in adults. There are 67,000 new cases of bladder cancer each year in the United States.

Southeastern Section of the AUA Virtual 85th Annual Meeting April 23 - 24, 2021 #SESAUA2021

UF Health Cancer Center Oncology Grand Rounds | February 10, 2021 | 12:00 PM

As prostate cancer is the most common genitourinary cancer treated by a urologist and by far the most visible cancer from the standpoint of public awareness, our UF Health Urology team members are doing their part to increase awareness of this challenging disease by wearing a light blue ribbon lapel pin throughout the duration of the month of September.